why choose us

First received: January 25, 2023

Clinical Trial: Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hepatic Impairment

Study Type: INTERVENTIONAL


Official Title: A Phase I, Single Dose, Non-Randomised, Multicentre, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant i

Brief Summary: This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe hepatic impairment compared with post-menopausal female participants with normal hepatic function.Participants will be enrolled within the following groups based on their CP classification score as determined at screening:Group 1: Matched-control healthy participants with normal hepatic…

Read more